DDX53 and neoplasm: While MLN4924 hardly inhibited CT26 tumor growth, and either MEK inhibitor or anti-PD-L1 antibody moderately restricted tumor growth, the combination of MLN4924 with MEK inhibitor or particularly with anti-PD-L1 antibody significantly enhanced suppression of tumor growth (Figs. 6C–E and S7B).